Literature DB >> 2767105

Cell kinetics as a prognostic indicator in node-negative breast cancer.

R Silvestrini1, M G Daidone, P Valagussa, G Di Fronzo, G Mezzanotte, G Bonadonna.   

Abstract

The consistency of the prognostic role of cell kinetics (evaluated as the [3H]thymidine labeling index, LI) over a period of years has been assessed in 354 patients with resectable node-negative breast cancer subjected only to Halsted or modified radical mastectomy. The risk of disease recurrence and death was proportional to LI values and the pattern was superimposable, regardless of menopausal status, in the two consecutive case series entered in this retrospective study. In particular, tumors with high LI (greater than 2.8%) had a higher 6-year probability (41% vs. 25%, P less than 0.0001) of manifesting local-regional and distant metastases and of dying (19% vs. 5%, P = 0.0005) as compared to tumors with low LI. In tumors with high LI the risk of relapse within the first 2 years from mastectomy was twofold compared to that of tumors with low LI. Multiple regression analysis showed that LI also retained its prognostic significance in both relapse-free and overall survival when tumor size and estrogen receptor status were considered. The present findings confirm that LI can substantially contribute to the selection of high risk node-negative patients who could be candidates for adjuvant chemotherapy.

Entities:  

Mesh:

Year:  1989        PMID: 2767105     DOI: 10.1016/0277-5379(89)90410-0

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  16 in total

1.  Determination of cell proliferation.

Authors:  D M Barnes; C E Gillett
Journal:  Clin Mol Pathol       Date:  1995-02

2.  Comparison between different cell kinetic variables in human breast cancer.

Authors:  F Barzanti; M Dal Susino; A Volpi; D Amadori; A Riccobon; E Scarpi; L Medri; L Bernardi; S Naldi; M Aldi; M Gaudio; W Zoli
Journal:  Cell Prolif       Date:  2000-04       Impact factor: 6.831

Review 3.  Endocrine therapy for advanced breast cancer: a review.

Authors:  H B Muss
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

4.  Randomised clinical trial of adjuvant chemotherapy in patients with node-negative, fast-proliferating breast cancer.

Authors:  A Paradiso; A Mangia; A Barletta; A M Catino; A Giannuzzi; F Schittulli; N Radogna; S Longo; D Palmieri; F Marzullo
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 5.  Natural history of human breast cancer: recent data and clinical implications.

Authors:  M Tubiana; S Koscielny
Journal:  Breast Cancer Res Treat       Date:  1991-08       Impact factor: 4.872

6.  Cell kinetics and hormonal features in relation to pathological stage in breast cancer.

Authors:  D Amadori; C Bonaguri; O Nanni; P Gentilini; N Lundi; W Zoli; A Riccobon; A Vio; E Magni; A Saragoni
Journal:  Breast Cancer Res Treat       Date:  1991-03       Impact factor: 4.872

7.  Proliferative activity of breast cancers increases in the course of genetic evolution as defined by cytogenetic analysis.

Authors:  Y Remvikos; M Gerbault-Seureau; H Magdelénat; M Prieur; B Dutrillaux
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

8.  3H-thymidine labeling index, hormone receptors, and ploidy in breast cancers from elderly patients.

Authors:  B Valentinis; R Silvestrini; M G Daidone; D Coradini; E Galante; A M Cerrotta; G Abolafio; L Arboit
Journal:  Breast Cancer Res Treat       Date:  1991-12       Impact factor: 4.872

9.  Tumor proliferative activity and response to first-line chemotherapy in advanced breast carcinoma.

Authors:  A Bonetti; M Zaninelli; S Rodella; A Molino; L Sperotto; Q Piubello; F Bonetti; R Nortilli; M Turazza; G L Cetto
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

10.  Relationship of variations in tumor cell kinetics induced by primary chemotherapy to tumor regression and prognosis in locally advanced breast cancer.

Authors:  G Gardin; A Alama; R Rosso; E Campora; L Repetto; P Pronzato; L Merlini; C Naso; A Camoriano; R Meazza
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.